Persistence and and optimization of baricitinib in rheumatoid arthritis in real-world practice: survival analysis, causes of discontinuation, and predictive factors

Olumiant (baricitinib) - Eli Lilly

Persistence and and optimization of baricitinib in rheumatoid arthritis in real-world practice: survival analysis, causes of discontinuation, and predictive factors (ACR Convergence 2026) - Sep 8, 2026 - Abstract #461; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Baricitinib shows high persistence ( >2.8 years) in real-world practice, primarily limited by inefficacy. Early use significantly favors survival. A greater number of prior DMARDs is associated with reduced treatment persistence."
Biomarker • Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Herpes Zoster • Hypertension • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome • Varicella Zoster

https://acrabstracts.org/abstract/persistence-and-and-optimization-of-baricitinib-in-rheumatoid-arthritis-in-real-world-practice-survival-analysis-causes-of-discontinuation-and-predictive-factors/

Daniel Campos1; César Antonio Egües Dubuc2; Nerea Alcorta Lorenzo3; Luis María López Domínguez1; Carlos María Lizasoain Alustiza4; Jon Aleman1; María-Teresa Iglesias-Gaspar1; Maria Asunción Aranguren Redondo4; Joaquin Maria Belzunegui Otano5

Sep 8, 2026